Document:

EX-4.1

 Exhibit 4.1 

BAXALTA INCORPORATED 

2015 INCENTIVE PLAN 

SECTION 1 

GENERAL 
 1.1
Purpose. Baxalta Incorporated, a Delaware corporation (“Baxalta”), has established the Baxalta Incorporated 2015 Incentive Plan (“Plan”) to increase shareholder value and to advance the interests of Baxalta and the
Subsidiaries (collectively, the “Company”) by providing a variety of economic incentives designed to motivate, retain and attract employees, directors, consultants, independent contractors, agents, and other persons providing services to
the Company. At the time of adoption of the Plan, Baxalta is a wholly-owned subsidiary of Baxter International Inc. (“Baxter”), and the Plan has been approved by Baxter as the sole shareholder of Baxalta. Baxter has entered into an
agreement with Baxalta pursuant to which Baxter will transfer its biopharmaceutical business to Baxalta, and distribute not less than 80% of the stock of Baxalta to Baxter’s shareholders, so that Baxalta will become a separate publicly traded
company, on or about July 1, 2015. 
 SECTION 2 

DEFINED TERMS 
 The
meaning of capitalized terms used in the Plan are set forth below if not otherwise defined in the text of the Plan. 
  

	 	(a)	“Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act. 

  

	 	(b)	“Agreement” shall have the meaning set forth in subsection 8.11. 

  

	 	(c)	“Award” means any award described in Section 6 or 7 of the Plan. 

  

	 	(d)	“Baxalta” means Baxalta Incorporated, a Delaware corporation. 

  

	 	(e)	“Baxter” means Baxter International Inc., a Delaware corporation, that, at the time of the adoption of the Plan, is the sole shareholder of Baxalta. 

 

	 	(f)	“Baxter Participant” means an employee or former employee of Baxter, or an outside director or former outside director of Baxter, who will not become an employee or outside director of Baxalta pursuant to the
Spin-Off, and who is entitled to receive a Spin-Off Award pursuant to Section 8.5. 

  

	 	(g)	 “Beneficiary” means, to the extent applicable, the person or persons the Participant designates to receive the balance of his or her
benefits under the Plan in the event of the Participant’s death. Any designation of a Beneficiary shall be in writing, signed by the Participant and filed with the Committee prior to the Participant’s death. A Beneficiary designation shall
be effective when filed with the Committee in accordance with the preceding sentence. If more than one Beneficiary has been designated, the balance of the Participant’s benefits under

	 	
the Plan shall be distributed to each such Beneficiary per capita. In the absence of a Beneficiary designation or if no Beneficiary survives the Participant, the Beneficiary shall be the
Participant’s estate. 

  

	 	(h)	“Board” means the Board of Directors of Baxalta. 

  

	 	(i)	“Cash Incentive Award” has the meaning set forth in subsection 7.1(b). 

  

	 	(j)	“Code” means the Internal Revenue Code of 1986, as amended. 

  

	 	(k)	“Committee” has the meaning set forth in subsection 3.1. 

  

	 	(l)	“Effective Date” has the meaning set forth in subsection 8.1. 

  

	 	(m)	“Eligible Individual” means any officer, director, or other employee of Baxalta or a Subsidiary, consultants, independent contractors or agents of Baxalta or a Subsidiary, and persons who are expected to
become officers, employees, directors, consultants, independent contractors or agents of Baxalta or a Subsidiary, including, in each case, directors who are not employees of Baxalta or a Subsidiary. In addition, a Baxter Participant shall be
considered an Eligible Individual, but only with respect to Spin-Off Awards. 

  

	 	(n)	“Employee Matters Agreement” means the Employee Matters Agreement, by and between Baxter and Baxalta. 

  

	 	(o)	“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

  

	 	(p)	“Expiration Date” has the meaning set forth in subsection 6.9. 

  

	 	(q)	“Fair Market Value” of a Share means, as of any date and except as otherwise provided by the Committee, the closing sale price of a Share as reported on the New York Stock Exchange Composite Tape (or if the
Shares are not traded on the New York Stock Exchange, the closing sale price on the exchange on which they are traded or as reported by an applicable automated quotation system) (“Composite Tape”) on the applicable date or, if no sales of
Shares are reported on such date, the closing sale price of a Share on the date a sale was last reported on the Composite Tape (or such other exchange or automated quotation system, if applicable). For purposes of determining the Fair Market Value
of Shares that are sold pursuant to a cashless exercise program, Fair Market Value shall be the price at which such Shares are sold. 

  

	 	(r)	“Full Value Award” has the meaning set forth in subsection 7.1(a). 

  

	 	(s)	“Grant Date” shall mean the date as of which an Award is approved and as provided in the Agreement governing such Award, or such later date as may be required by applicable local law in the case of an Award
granted to a Participant outside of the United States. 

  
 2 

	 	(t)	“Incentive Stock Option” means an Option that is intended to satisfy the requirements applicable to an “incentive stock option” described in section 422 of the Code. 

 

	 	(u)	“Non-Qualified Stock Option” means an Option that is not intended to be an Incentive Stock Option. 

  

	 	(v)	“Option” has the meaning set forth in subsection 6.1(a). 

  

	 	(w)	“Outside Director” means a director of Baxalta who is not an officer or employee of Baxalta or any Subsidiary. 

  

	 	(x)	“Participant” shall have the meaning set forth in Section 4. 

  

	 	(y)	“Performance-Based Compensation” shall have the meaning set forth in subsection 7.2. 

  

	 	(z)	 “Performance Criteria” means performance targets based on one or more of the following criteria: (i) sales or net sales;
(ii) gross profit or margin; (iii) expenses, including cost of goods sold, operating expenses, marketing and administrative expense, research and development, restructuring or other special or unusual items, interest, tax expense, or other
measures of savings; (iv) operating earnings, earnings before interest, taxes, depreciation, or amortization, net earnings, earnings per share (basic or diluted) or other measure of earnings; (v) cash flow, including cash flow from
operations, investing, or financing activities, before or after dividends, investments, or capital expenditures; (vi) balance sheet performance, including debt, long or short term, inventory, accounts payable or receivable, working capital, or
shareholders’ equity; (vii) return measures, including return on invested capital, sales, assets, or equity; (viii) stock price performance or shareholder return; (ix) economic value created or added; (x) implementation or
completion of critical projects, including acquisitions, divestitures, and other ventures, process improvements, product or production quality, attainment of other strategic objectives, including market penetration, geographic expansion, product
development, regulatory or quality performance, innovation or research goals, or the like. In each case, performance may be measured (A) on an aggregate or net basis; (B) before or after tax or cumulative effect of accounting changes;
(C) relative to other approved measures, on an aggregate or percentage basis, over time, or as compared to performance by other companies or groups of other companies; or (D) by product, product line, business unit or segment, or
geographic unit. The performance targets may include a threshold level of performance below which no payment will be made (or no vesting will occur), levels of performance at which specified payments will be made (or specified vesting will occur),
and a maximum level of performance above which no additional payment will be made (or at which full vesting will occur). Where applicable, each of the foregoing performance targets shall be determined in accordance with generally accepted accounting
principles and shall be subject to certification by the Committee; provided that the Committee shall 

  
 3 

	 	
have the authority to exclude the impact of charges for restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring, special, or non-recurring events,
asset write downs, litigation or claim judgments or settlements, reorganization or change in the capital structure of Baxalta, foreign exchange gains or losses and the cumulative effects of tax or accounting principles as identified in financial
results filed with or furnished to the Securities and Exchange Commission. Any performance goals that are financial metrics, may be determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), in accordance with
accounting principles established by the International Accounting Standards Board (“IASB Principles”), or may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP or under IASB
Principles. 

  

	 	(aa)	“Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) Baxalta or any of
its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of Baxalta or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or
(iv) a corporation owned, directly or indirectly, by the shareholders of Baxalta in substantially the same proportions as their ownership of stock of Baxalta. 

 

	 	(bb)	“SAR” or “Stock Appreciation Right” has the meaning set forth in subsection 6.1(b). 

  

	 	(cc)	“Share” means a share of common stock, $.01 par value, of Baxalta, as adjusted in accordance with Section 5.2 of the Plan. 

 

	 	(dd)	“Spin-Off” means the transaction pursuant to which Baxter will transfer the assets of its biopharmaceutical business to Baxalta and distribute at least 80.1 % of the Shares to the shareholders of Baxter,
resulting in Baxalta becoming an independent publicly traded company. 

  

	 	(ee)	“Spin-Off Award” means an Award granted to a Baxter Participant pursuant to Section 8.5. 

  

	 	(ff)	“Subsidiary” means any corporation, partnership, joint venture or other entity during any period in which a controlling interest in such entity is owned, directly or indirectly, by Baxalta (or by any entity
that is a successor to Baxalta), and any other business venture designated by the Committee in which Baxalta (or any entity that is a successor to Baxalta) has, directly or indirectly, a significant interest (whether through the ownership of
securities or otherwise), as determined in the discretion of the Committee. Notwithstanding the foregoing, in the case of an Incentive Stock Option or any determination relating to an Incentive Stock Option, “Subsidiary” means a
corporation that is a subsidiary of Baxalta within the meaning of section 424(f) of the Code. 

  
 4 

	 	(gg)	“Substitute Award” means an Award granted or Shares issued by Baxalta in assumption of, or in substitution or exchange for, an award previously granted, or the right or obligation to make a future award, in
all cases by a company acquired by Baxalta or any Subsidiary or with which Baxalta or any Subsidiary combines. 

  

	 	(hh)	“Termination Date” means the date on which a Participant both ceases to be an employee of the Company and ceases to perform material services for the Company (whether as a director or otherwise), regardless of
the reason for the cessation; provided that a “Termination Date” shall not be considered to have occurred during the period in which the reason for the cessation of services is a leave of absence approved by Baxalta or the Subsidiary which
was the recipient of the Participant’s services; and provided, further that, with respect to an Outside Director, “Termination Date” means date on which the Outside Director’s service as an Outside Director terminates for any
reason. 

 SECTION 3 

ADMINISTRATION  

3.1 Administration By Committee. The authority to control and manage the operation and administration of the Plan shall
be vested in the committee described in subsection 3.2 (the “Committee”) in accordance with this Section 3. If the Committee does not exist, or for any other reason determined by the Board, the Board may take any action under the Plan
that would otherwise be the responsibility of the Committee. 
 3.2 Selection of Committee. So long as Baxalta is
subject to Section 16 of the Exchange Act, the Committee shall be selected by the Board and shall consist of not fewer than two members of the Board or such greater number as may be required for compliance with Rule 16b-3 issued under the
Exchange Act and shall be comprised of persons who are independent for purposes of applicable stock exchange listing requirements. Any Award granted under the Plan that is intended to constitute Performance-Based Compensation (including Options and
SARs) shall be granted by a Committee consisting solely of two or more “outside directors” within the meaning of section 162(m) of the Code and applicable regulations; provided, however, that as of the Effective Date and continuing
thereafter unless and until otherwise specified by the Board, the Committee shall be the Compensation Committee of the Board. Notwithstanding any other provision of the Plan to the contrary, with respect to any Awards to Outside Directors, the
Committee shall be the Board. 
 3.3 Powers of Committee. The authority to manage and control the operation and
administration of the Plan shall be vested in the Committee, subject to the following: 
  

	 	(a)	Subject to the provisions of the Plan (including subsection 3.3(e)), the Committee will have the authority and discretion to (i) select Eligible Individuals who will receive Awards under the Plan,
(ii) determine the time or times of receipt of Awards, (iii) determine the types of Awards and the number of Shares covered by the Awards, (iv) establish the terms, conditions, performance targets, restrictions, and other provisions
of such Awards, (v) modify the terms of, cancel, or suspend Awards; (vi) reissue or repurchase Awards, and (vii) accelerate the exercisability 

  
 5 

	 	
or vesting of any Award. In making such Award determinations, the Committee may take into account the nature of services rendered by the respective individual, the individual’s present and
potential contribution to Baxalta’s or a Subsidiary’s success and such other factors as the Committee deems relevant. 

  

	 	(b)	Subject to the provisions of the Plan, the Committee will have the authority and discretion to determine the extent to which Awards under the Plan will be structured to conform to the requirements applicable to
Performance-Based Compensation, and to take such action, establish such procedures, and impose such restrictions at the time such Awards are granted as the Committee determines to be necessary or appropriate to conform to such requirements.

  

	 	(c)	Subject to the provisions of the Plan, the Committee will have the authority and discretion to conclusively interpret the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, to
determine the terms and provisions of any agreements made pursuant to the Plan, to remedy any defect or omission and reconcile any inconsistency in the Plan or any Award, and to make all other determinations that may be necessary or advisable for
the administration of the Plan including the termination thereof. 

  

	 	(d)	Any interpretation of the Plan by the Committee and any decision made by it under the Plan is final and binding on all persons. 

  

	 	(e)	Except as otherwise expressly provided in the Plan, where the Committee is authorized to make a determination with respect to any Award, such determination shall be made at the time the Award is made, except that the
Committee may reserve the authority to have such determination made by the Committee in the future (but only if such reservation is made at the time the Award is granted is expressly stated in the Agreement reflecting the Award and is permitted by
applicable law); provided that nothing contained herein shall be construed to limit the Committee’s authority to modify the terms of, cancel, or suspend outstanding Awards, reissue or repurchase outstanding Awards, or accelerate the
exercisability or vesting of any outstanding Award to the extent such action is otherwise permissible under the Plan. 

3.4 Delegation by Committee. Except to the extent prohibited by applicable law or the rules of any stock exchange, the
Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any part of its responsibilities and powers to any person or persons selected by it. Any such allocation or
delegation may be revoked by the Committee at any time. 
 3.5 Information to be Furnished to Committee. The Company
shall furnish the Committee such data and information as may be required for it to discharge its duties. The records of the Company as to an individual’s employment or provision of services, termination of employment or cessation of the
provision of services, leave of absence, reemployment and compensation shall be conclusive on all persons unless determined to be incorrect. Participants and other persons entitled to benefits under the Plan must furnish the Committee such evidence,
data or information as the Committee consider desirable to carry out the terms of the Plan. 

  
 6 

 3.6 Liability and Indemnification of Committee. No member or authorized
delegate of the Committee shall be liable to any person for any action taken or omitted in connection with the administration of the Plan unless attributable to his own fraud or willful misconduct; nor shall Baxalta or any Subsidiary be liable to
any person for any such action unless attributable to fraud or willful misconduct on the part of a director or employee of Baxalta or a Subsidiary. The Committee, the individual members thereof, and persons acting as the authorized delegates of the
Committee under the Plan, shall be indemnified by Baxalta against any and all liabilities, losses, costs and expenses (including legal fees and expenses) of whatsoever kind and nature which may be imposed on, incurred by or asserted against the
Committee or its members or authorized delegates by reason of the performance of a Committee function if the Committee or its members or authorized delegates did not act dishonestly or in willful violation of the law or regulation under which such
liability, loss, cost or expense arises. This indemnification shall not duplicate but may supplement any coverage available under any applicable insurance. 

SECTION 4 

PARTICIPATION  

Subject to the terms and conditions of the Plan, a “Participant” in the Plan is any Eligible Individual to whom an Award is granted
under the Plan. Subject to the terms and conditions of the Plan, the Committee shall determine and designate, from time to time, from among the Eligible Individuals those persons who will be granted one or more Awards under the Plan and, subject to
the terms and conditions of the Plan, a Participant may be granted any Award permitted under the provisions of the Plan and more than one Award may be granted to a Participant. Except as otherwise agreed by Baxalta and the Participant, or except as
otherwise provided in the Plan, an Award under the Plan shall not affect any previous Award under the Plan or an award under any other plan maintained by Baxalta or any Subsidiary. 

SECTION 5 

SHARES RESERVED AND LIMITATIONS  

5.1 Shares and Other Amounts Subject to the Plan. The Shares for which Awards may be granted under the Plan shall be
subject to the following: 
  

	 	(a)	The Shares with respect to which Awards may be made under the Plan shall be shares currently authorized but unissued or currently held or subsequently acquired by Baxalta as treasury shares, including shares purchased
in the open market or in private transactions. 

  

	 	(b)	 Subject to the provisions of subsection 5.2, the number of Shares which may be issued with respect to Awards under the Plan, including the Spin-Off
Awards, shall be equal to Ninety-One Million (91,000,000) Shares. Except as otherwise provided herein, any Shares subject to an Award, including a Spin-Off Award, which for any reason expires or is forfeited, cancelled, surrendered, or
terminated without issuance of Shares (including Shares attributable to Awards that are 

  
 7 

	 	
settled in cash) shall again be available under the Plan. Shares subject to an Award under the Plan may not again be made available for issuance under the Plan if such Shares are: (i) Shares
that were subject to a stock-settled SAR and were not issued or delivered upon the net settlement of such SAR; (ii) Shares delivered to or withheld by Baxalta to pay the exercise price or the withholding taxes related to an outstanding Award;
and (iii) Shares repurchased on the open market with the proceeds of an Option exercise. 

  

	 	(c)	Any Shares subject to Full Value Awards shall be counted against the Ninety-One Million (91,000,000) limit described in Section 5.1(b) as three (3) Shares for every one (1) Share issued in connection
with such Award. If Shares subject to any such Full Value Award are forfeited, cancelled, surrendered, or terminated without issuance of Shares and would otherwise return to the Plan pursuant to Section 5.1(b), three (3) times the number
of Shares so forfeited, cancelled, surrendered or terminated shall again be available for issuance under the Plan. 

  

	 	(d)	Substitute Awards shall not reduce the Shares that may be issued under the Plan or that may be covered by Awards granted to any one Participant during any calendar year pursuant to subsection 5.1(h) or subsection
5.1(i). 

  

	 	(e)	Except as expressly provided by the terms of this Plan, the issuance by Baxalta of shares of stock of any class, or securities convertible into shares of stock of any class, for cash or property or for labor or
services, either upon direct sale, upon the exercise of rights or warrants to subscribe therefor or upon conversion of shares or obligations of Baxalta or any Subsidiary convertible into such shares or other securities, shall not affect, and no
adjustment by reason thereof, shall be made with respect to Awards then outstanding hereunder. 

  

	 	(f)	To the extent provided by the Committee, any Award may be settled in cash rather than in Shares. 

  

	 	(g)	Subject to the following provisions of this subsection 5.1, the maximum number of Shares that may be delivered to Participants and their Beneficiaries with respect to Incentive Stock Options under the Plan shall be
Ninety-One Million (91,000,000); provided, however, that to the extent that shares not delivered must be counted against this limit as a condition of satisfying the rules applicable to Incentive Stock Options, such rules shall apply to the limit on
Incentive Stock Options granted under the Plan. 

  

	 	(h)	The maximum number of Shares that may be covered by Awards granted to any one Participant during any one calendar-year period pursuant to Section 6 (relating to Options and SARs) shall be 2 million, not
including any Spin-Off Awards. For purposes of this subsection 5.1(h), if an Option is in tandem with an SAR, such that the exercise of the Option or SAR with respect to a Share cancels the tandem SAR or Option right, respectively, with respect to
such share, the tandem Option and SAR rights with respect to each Share shall be counted as covering but one Share for purposes of applying the limitations of this subsection 5.1(h). 

  
 8 

	 	(i)	For Full Value Awards that are intended to be Performance-Based Compensation, no more than 500,000 Shares may be subject to Awards, not including Spin-Off Awards, granted to any one Participant during any
one-calendar-year period (regardless of whether settlement of the Award is to occur prior to, at the time of, or after the time of vesting); provided that Awards described in this 5.1(i) that are intended to be Performance-Based Compensation shall
be subject to the following: 

  

	 	(i)	If the Awards are denominated in Shares but an equivalent amount of cash is delivered in lieu of delivery of Shares, the foregoing limit shall be applied based on the methodology used by the Committee to convert the
number of Shares into cash. 

  

	 	(ii)	If delivery of Shares or cash is deferred until after Shares have been earned, any adjustment in the amount delivered to reflect actual or deemed investment experience after the date the Shares are earned shall be
disregarded. 

  

	 	(j)	For Cash Incentive Awards that are intended to be Performance-Based Compensation, the maximum amount payable to any Participant with respect to all performance periods ending in a single calendar year shall equal
$10,000,000; provided that Awards described in this subsection 5.1(j) that are intended to be Performance-Based Compensation, shall be subject to the following: 

  

	 	(i)	If the Awards are denominated in cash but an equivalent amount of Shares is delivered in lieu of delivery of cash, the foregoing limit shall be applied to the cash based on the methodology used by the Committee to
convert the cash into Shares. 

  

	 	(ii)	If delivery of Shares or cash is deferred until after cash has been earned, any adjustment in the amount delivered to reflect actual or deemed investment experience after the date the cash is earned shall be
disregarded. 

 5.2 Adjustments to Shares. In the event a stock dividend, stock split, reverse stock
split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, distribution, split-up, spin-off, exchange of shares, or similar corporate transaction affects the Shares such that the Committee determines, in its sole
discretion, that an adjustment is warranted in order to preserve the benefits or prevent the enlargement of benefits of Awards under the Plan, then the Committee shall, in the manner it deems equitable, (a) adjust the number and kind of shares
that may be delivered under the Plan (including adjustments to the number and kind of shares that may be granted to an individual during any specified time as described in subsection 5.1, except that any such adjustment may increase the number of
Shares subject to Incentive Stock Options only if permitted by section 422 of the Code); (b) adjust the number and kind of 

  
 9 

 
shares subject to outstanding Awards; (c) adjust the number and Exercise Price of outstanding Options and SARs; and (d) make other adjustments, including, without limitation,
(i) replacement of Awards with other Awards that the Committee determines have comparable value and are based on stock of a company resulting from or involved in the transaction, and (ii) cancellation of the Award in return for cash
payment of the current value of the Award, determined as though the Award is fully vested at the time of payment. For purposes of the preceding sentence, the value of an Option or SAR shall be equal to the excess, if any, of the Fair Market Value of
a Share over the Exercise Price, multiplied by the number of Shares subject to the Option or SAR, and if the Fair Market Value of a Shares does not exceed the Exercise Price, the Option or SAR may be cancelled without payment of any consideration.

 SECTION 6 

OPTIONS AND SARS  

6.1 Definitions.  
  

	 	(a)	The grant of an “Option” under the Plan entitles the Participant to purchase Shares at an Exercise Price established by the Committee at the time the Option is granted. Options granted under this
Section 6 may be either Incentive Stock Options or Non-Qualified Stock Options, as determined in the discretion of the Committee; provided, however, that Incentive Stock Options may only be granted to employees of Baxalta or a Subsidiary. An
Option will be deemed to be a Non-Qualified Stock Option unless it is specifically designated by the Committee as an Incentive Stock Option. 

  

	 	(b)	A grant of a “stock appreciation right” or “SAR” entitles the Participant to receive, in cash or Shares (as determined in accordance with the terms of the Plan), value equal to the excess of:
(i) the Fair Market Value of a specified number of Shares at the time of exercise; over (ii) an Exercise Price established by the Committee at the time of grant. 

 

	 	(c)	An Option may but need not be in tandem with an SAR, and an SAR may but need not be in tandem with an Option (in either case, regardless of whether the original award was granted under this Plan or another plan or
arrangement). If an Option is in tandem with an SAR, the Exercise Price of both the Option and SAR shall be the same, and the exercise of the Option or SAR with respect to a Share shall cancel the corresponding tandem SAR or Option right with
respect to such share. 

 6.2 Eligibility. The Committee shall designate the Participants to whom Options
or SARs are to be granted under this Section 6 and shall determine the number of Shares subject to each such Option or SAR and the other terms and conditions thereof, not inconsistent with the Plan. Without limiting the generality of the
foregoing, the Committee may grant dividend equivalents (current or deferred) with respect to any Option or SAR granted under the Plan; provided that dividend equivalents shall either be paid at the same time that dividends are paid with respect to
Shares or shall be deferred and paid only at the time (and to the extent) the Option or SAR vests, but in no event shall payment of dividend equivalents be conditioned upon exercise of the Option or SAR. 

  
 10 

 6.3 Limits on Incentive Stock Options. If the Committee grants Incentive
Stock Options, then to the extent that the aggregate Fair Market Value of Shares (as determined on the Grant Date) with respect to which Incentive Stock Options are exercisable for the first time by any individual during any calendar year (under all
plans of the Company) exceeds $100,000, such Options shall be treated as Non-Qualified Stock Options to the extent required by section 422 of the Code. 

6.4 Exercise Price. The “Exercise Price” of an Option or SAR shall be established by the Committee at the time
the Option or SAR is granted; provided, however, that in no event shall such price be less than 100% of the Fair Market Value of a Share on such date (or, if greater, the par value of a Share on such date), except with respect to Spin-Off Awards as
provided in Section 8.5. 
 6.5 Exercise/Vesting. Except as otherwise expressly provided in the Plan, an Option or
SAR granted under the Plan shall be exercisable in accordance with the following: 
  

	 	(a)	An Option or SAR granted under this Section 6 shall be exercised, in whole or in part (but with respect to whole Shares only) by giving notice to Baxalta prior to the Expiration Date applicable thereto. Such notice
shall specify the number of Shares being exercised and such other information as may be required by the Committee. 

  

	 	(b)	No Option or SAR may be exercised prior to the date on which it is exercisable (or vested) or after the Expiration Date. 

  

	 	(c)	The terms and conditions relating to exercise and vesting of an Option or SAR shall be established by the Committee to the extent not inconsistent with the Plan, and may include, without limitation, conditions relating
to completion of a specified period of service, achievement of performance standards prior to exercise or the achievement of Share ownership objectives by the Participant. 

6.6 Payment of Exercise Price. The payment of the Exercise Price of an Option granted under this Section 6 shall be
subject to the following: 
  

	 	(a)	Subject to the following provisions of this subsection 6.6, the full Exercise Price of each Share purchased upon the exercise of any Option shall be paid at the time of such exercise (except that, in the case of an
exercise through the use of cash equivalents, payment may be made as soon as practicable after the exercise) and, as soon as practicable thereafter, a certificate representing the Shares so purchased shall be delivered to the person entitled
thereto. 

  

	 	(b)	Subject to applicable law, the Exercise Price shall be payable in cash or cash equivalents, by tendering, by actual delivery or by attestation, Shares valued at Fair Market Value as of the day of exercise or by a
combination thereof; provided, however, that Shares may not be used to pay any portion of the Exercise Price unless the holder thereof has good title, free and clear of all liens and encumbrances. 

  
 11 

	 	(c)	With the approval of the Committee, a Participant may pay the Exercise Price for an Option in whole or in part either through a broker-assisted cashless exercise, by having a number of Shares with a fair market value
equal to the Exercise Price withheld from the number of Shares delivered to the Participant, or by any other method permitted by the Committee in accordance with applicable law. 

6.7 Post-Exercise Limitations. The Committee, in its discretion, may provide in an Award such restrictions on Shares
acquired pursuant to the exercise of an Option as it determines to be desirable, including, without limitation, restrictions relating to disposition of the shares and forfeiture restrictions based on service, performance, Share ownership by the
Participant and such other factors as the Committee determines to be appropriate. 
 6.8 No Repricing. Except for
adjustments pursuant to subsection 5.2 (relating to the adjustment of Shares) or reductions of the Exercise Price approved by Baxalta’s shareholders, the Exercise Price for any outstanding Option or SAR may not be decreased after the date of
grant nor may (i) an outstanding Option or SAR granted under the Plan be surrendered to Baxalta as consideration for the grant of a replacement Option or SAR with a lower Exercise Price, or (ii) an outstanding Option or SAR the Exercise
Price of which exceeds the Fair Market Value of the Shares be repurchased or surrendered in consideration of a cash payment. In addition, no repricing of an Option or SAR shall be permitted without the approval of Baxalta’s shareholders if such
approval is required under the rules of any stock exchange on which Shares are listed. 
 6.9 Expiration Date. The
“Expiration Date” with respect to an Option or SAR means the date established as the Expiration Date by the Committee at the time of the grant; provided, however, that in no event shall the Expiration Date of an Option or SAR be later than
the date that is ten years after the date on which the Option or SAR is granted (or such shorter period required by law or the rules of any stock exchange). 

SECTION 7 

FULL VALUE AWARDS AND CASH INCENTIVE AWARDS  

7.1 Definitions.  
  

	 	(a)	A “Full Value Award” is a grant of one or more Shares or a right to receive one or more Shares in the future (including restricted shares, restricted share units, deferred shares, deferred share units,
performance shares, dividend equivalent units and performance share units), with such grant subject to one or more of the following, as determined by the Committee: 

 

	 	(i)	The grant may be in consideration of a Participant’s previously performed services, or surrender of other compensation that may be due. 

 

	 	(ii)	The grant may be contingent on the achievement of performance or other objectives during a specified period. 

  
 12 

	 	(iii)	The grant may be subject to a risk of forfeiture or other restrictions that will lapse upon the achievement of one or more goals relating to completion of service by the Participant or achievement of performance or
other objectives. 

  

	 	(iv)	The grant may also be subject to such other conditions, restrictions and contingencies, as determined by the Committee, including provisions relating to dividend or dividend equivalent rights and deferred payment or
settlement, provided that dividend equivalents shall either be paid at the same time that dividends are paid with respect to Shares or shall be deferred and paid only at the time (and to the extent) the Full Value Award vests. 

 

	 	(b)	A “Cash Incentive Award” is the grant of a right to receive a payment of cash (or in the discretion of the Committee, Shares having value equivalent to the cash otherwise payable) that is contingent on
achievement of performance objectives over a specified period established by the Committee. The grant of Cash Incentive Awards may also be subject to such other conditions, restrictions and contingencies, as determined by the Committee, including
provisions relating to deferred payment. 

 7.2 Performance-Based Compensation. Any Full Value Award or
Cash Incentive Award granted to any Participant may constitute “Performance-Based Compensation” within the meaning of section 162(m) of the Code and regulations thereunder. If any such award is intended to satisfy the requirements for
Performance-Based Compensation under section 162(m) of the Code, then to the extent required by section 162(m), any Full Value Award or Cash Incentive Award so designated shall be conditioned on the achievement of one or more performance targets as
determined by the Committee and the following additional requirements shall apply: 
  

	 	(a)	The performance targets established for the performance period established by the Committee shall be objective (as that term is described in regulations under section 162(m) of the Code), and shall be established in
writing by the Committee not later than 90 days after the beginning of the performance period (but in no event after 25% of the performance period has elapsed), and while the outcome as to the performance targets is substantially uncertain. The
performance targets established by the Committee shall be based on one or more of the Performance Criteria. 

  

	 	(b)	A Participant otherwise entitled to receive a Full Value Award or Cash Incentive Award for any performance period shall not receive a settlement or payment of the Award until the Committee has determined that the
applicable performance target(s) have been attained. To the extent that the Committee exercises discretion in making the determination required by this subsection 7.2(b), such exercise of discretion may not result in an increase in the amount of the
payment. 

  

	 	(c)	If a Participant’s Termination Date occurs because of death or disability, the Participant’s Full Value Award or Cash Incentive Award may become vested as determined by the Committee without regard to whether
the Full Value Award or Cash Incentive Award would be Performance-Based Compensation. 

  
 13 

 Nothing in this Section 7 shall preclude the Committee from granting Full Value Awards or
Cash Incentive Awards under the Plan or the Committee, Baxalta or any Subsidiary from granting any Cash Incentive Awards outside of the Plan that are not intended to be Performance-Based Compensation; provided, however, that to the extent that the
provisions of this Section 7 reflect the requirements applicable to Performance-Based Compensation, such provisions shall not apply to the portion of the Award, if any, that is not intended to constitute Performance-Based Compensation. 

SECTION 8 

OPERATION AND ADMINISTRATION  

8.1 Effective Date; Approval. The Plan will be effective as of the date it is adopted by the Board and approved by Baxter
in its capacity as sole shareholder (the “Effective Date”). The Plan shall be unlimited in duration and, in the event of Plan termination, shall remain in effect as long as any Shares awarded under it are outstanding and not fully vested
or any other Awards made under the Plan remain outstanding; provided, however, that no new Awards shall be made under the Plan on or after the tenth anniversary of the date on which the Plan is adopted by the Board. Notwithstanding the foregoing, no
Awards that are intended to constitute Performance-Based Compensation (including Options or SARs) may be granted after the first shareholder’s meeting that occurs at least twelve months after the effective date of the Spin-Off unless, at or
prior to such meeting, the shareholders approve the Plan in accordance with the regulations under section 162(m) of the Code. 
 8.2
Special Director Provisions. Notwithstanding any other provision of the Plan to the contrary, unless otherwise provided by the Board, awards to non-employee directors shall be made in accordance with the terms of the Baxalta
Incorporated Non-Employee Director Compensation Plan, as amended, and all such awards shall be deemed to be made under the Plan. 

8.3 Limit on Distribution. Distribution of Shares or other amounts under the Plan shall be subject to the following: 

 

	 	(a)	Notwithstanding any other provision of the Plan, Baxalta shall have no liability to deliver any Shares under the Plan or make any other distribution of benefits under the Plan unless such delivery or distribution would
comply with all applicable laws and the applicable requirements of any securities exchange or similar entity. 

  

	 	(b)	In the case of a Participant who is subject to Section 16(a) and 16(b) of the Exchange Act, the Committee may, at any time, add such conditions and limitations to any Award to such Participant, or any feature of
any such Award, as the Committee, in its sole discretion, deems necessary or desirable to comply with Section 16(a) or 16(b) and the rules and regulations thereunder or to obtain any exemption therefrom. 

 

	 	(c)	To the extent that the Plan provides for issuance of certificates to reflect the transfer of Shares, the transfer of such Shares may be effected on a non-certificated basis, to the extent not prohibited by applicable
law or the rules of any stock exchange. 

  
 14 

 8.4 Vesting upon Change in Control. Except as otherwise determined by the
Committee and set forth in an Agreement, the extent to which the vesting or exercisability of an Award is accelerated as a result of a Change in Control of the Company shall be as set forth below: 

(a) No Award that is not otherwise vested or exercisable shall become vested or exercisable solely as the result of the occurrence of a Change
in Control, except as otherwise determined by the Committee in accordance with Section 5.2(d)(ii) in the case of a Change in Control that results in the Company no longer being a publicly traded corporation, or in the assets or stock of the
Company being transferred to a successor that does not agree to assume the Company’s obligations under outstanding Awards. 
 (b) If a
Participant’s employment is terminated by the Company without Cause, or by the Participant for Good Reason, upon or within twenty-four (24) months following a Change in Control, the Participant’s Awards shall be fully vested and, in
the case of an Option or SAR, shall remain exercisable until the original Expiration Date of the Option or SAR; provided that, and, in the case of an Award the vesting of which is based in whole or part upon the attainment of performance goals, the
performance goals shall be deemed to have been met at the target level. The Committee may require a Participant to enter into an agreement containing restrictive covenants, including without limitation covenants not to compete, not to solicit
customers or employees, not to make use of confidential information, not to disparage the Company, or to cooperate with the Company in responding to claims about which the Participant has knowledge, as a condition to the application of the
provisions of this Section 8.4(b). 
  

	 	(c)	The following definitions shall apply for purposes of this Section 8.4: 

  

	 	(i)	“Cause” means (A) the willful and continued failure by the Participant to substantially perform his duties with the Company that has not been cured within 30 days after written demand for substantial
performance is delivered by the Company, which demand specifically identifies the manner in which the Participant has not substantially performed (other than any such failure resulting from the Participant’s incapacity due to physical or mental
illness), (B) the willful engaging by the Participant in conduct which is demonstrably and materially injurious to the Company, monetarily or otherwise, or (C) the engaging by the Participant in egregious misconduct involving serious moral
turpitude, determined in the reasonable judgment of the Committee. For purposes hereof, no act, or failure to act, on the Participant’s part shall be deemed “willful” unless done, or omitted to be done, by the Participant not in good
faith and without reasonable belief that such action was in the best interest of the Company. Notwithstanding the foregoing, if a Participant is a party to a Change in Control Agreement, “Cause” with respect to such Participant shall have
the meaning given to such term in the Change in Control Agreement. 

  
 15 

	 	(iii)	“Change in Control” means the first to occur of any of the following: (A) any Person is or becomes the beneficial owner (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of Baxalta (not including in the securities beneficially owned by such Person any securities acquired directly from Baxalta or its Affiliates) representing 30% or more of the combined voting power of Baxalta’s then outstanding
securities, excluding any Person who becomes such a beneficial owner in connection with a merger or consolidation of Baxalta or any direct or indirect subsidiary of Baxalta with any other corporation immediately following which the individuals who
comprise the Board immediately prior thereto constitute at least a majority of the board of directors of (1) any parent of Baxalta or the entity surviving such merger or consolidation or (2) if there is no such parent, of Baxalta or such
surviving entity; (B) the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the Grant Date, constitute the Board and any new director (other than a director whose
initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of Baxalta) whose appointment or election by the Board or
nomination for election by Baxalta’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the Grant Date or whose appointment, election or
nomination for election was previously so approved or recommended; (C) there is consummated a merger or consolidation of Baxalta or any direct or indirect subsidiary of Baxalta with any other corporation or other entity, other than a merger or
consolidation immediately following which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of (1) any parent of Baxalta or the entity surviving such merger or
consolidation or (2) if there is no such parent, of Baxalta or such surviving entity; or (D) the shareholders of Baxalta approve a plan of complete liquidation or dissolution of Baxalta or there is consummated an agreement for the sale or
disposition by Baxalta of all or substantially all of Baxalta’s assets, other than a sale or disposition by Baxalta of all or substantially all of Baxalta’s assets immediately following which the individuals who comprise the Board
immediately prior thereto constitute at least a majority of the board of directors of (1) any parent of Baxalta or of the entity to which such assets are sold or disposed or (2) if there is no such parent, of Baxalta or such entity. For
the avoidance of doubt, the Spin-Off shall not be considered a Change in Control. 

  

	 	(iii)	“Change in Control Agreement” means an employment agreement, change in control agreement or plan, severance agreement or plan, or other agreement between the Company and a Participant or Company plan covering
a Participant that provides for benefits upon termination for good reason or cause in connection with a Change in Control of Baxalta and that has been approved by the Board or the Committee. 

 

	 	(iv)	 “Good Reason” means the occurrence (without the Participant’s express written consent) of any of the following which occur on or after
a Change in Control: (A)

  
 16 

	 	
reduction by the Company in the Participant’s annual base salary as in effect on the Grant Date or as the same may be increased from time to time; (B) the relocation of the
Participant’s principal place of employment to a location more than fifty (50) miles from the Participant’s principal place of employment immediately prior to the Change in Control or the Company’s requiring the Participant to be
based anywhere other than such principal place of employment (or permitted relocation thereof) except for required travel on the Company’s business to an extent substantially consistent with the Participant’s business travel obligations as
in effect immediately prior to the Change in Control; or (C) the failure by the Company to pay to the Participant any portion of the Participant’s current compensation or to pay to the Participant any portion of an installment of deferred
compensation under any deferred compensation program of the Company, within seven (7) days of the date such compensation is due. Notwithstanding the foregoing, if a Participant is a party to a Change in Control Agreement, “Good
Reason” with respect to such Participant shall have the meaning given to such term in the Change in Control Agreement. 

8.5 Spin-Off Awards. Effective as of the date of the Spin-Off, each person who holds an Option, SAR, or Full Value Award
granted under the Baxter International Inc. 1998 Incentive Compensation Program, the Baxter International Inc. 2000 Incentive Compensation Program, the Baxter International Inc. 2001 Incentive Compensation Program, the Baxter International Inc. 2003
Incentive Compensation Program, the Baxter International Inc. 2007 Incentive Plan or the Baxter International Inc. 2011 Incentive Plan (each, a “Baxter Plan” and collectively, the “Baxter Plans”) shall, to the extent provided in
the Employee Matters Agreement, automatically and without further action by the Committee, be granted an Option, SAR or Full Value Award (a “Spin-Off Award”) under the terms and conditions set forth in the Employee Matters Agreement;
provided that Spin-Off Awards shall be granted to Baxter Participants only with respect to awards granted under the Baxter Plans on and after January 1, 2015 (July 1, 2014, in the case of a new hire or rehire awards). The vesting provisions of
any Spin-Off Award granted to a Baxter Participant shall be applied based upon the Baxter Participant’s continued employment by Baxter, and the date on which a Baxter Participant’s employment with Baxter and all of its Subsidiaries
terminates shall be considered the Baxter Participant’s Termination Date. If a Baxter Participant’s employment with Baxter is terminated by Baxter without Cause, or by the Participant for Good Reason, upon or within twenty-four
(24) months following a Change in Control of Baxter, the Participant’s Spin-Off Awards shall be fully vested and, in the case of an Option or SAR, shall remain exercisable until the original Expiration Date of the Option or SAR, to the
same extent as provided in Section 8.4(b). For purposes of the preceding sentence, the terms “Cause”, “Good Reason”, and “Change in Control” shall have the meanings provided in the applicable Baxter Plan, and for
all purposes of this Section 8.5 the Committee may rely conclusively upon any determination made by the compensation committee of Baxter (or any other person delegated the authority to administer the Baxter Plan), with regard to whether a
Change in Control of Baxter has occurred, and the reason for the Baxter Participant’s termination by Baxter. 
 8.6
Forfeitures and Clawbacks. Anything else contained in the Plan or any Agreement to the contrary notwithstanding: 

  
 17 

 (a) The Committee may specify in an Agreement that the Participant’s rights, payments, and
benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture (including repurchase of Shares for nominal consideration), or recoupment upon the occurrence of certain specified events, in addition to any otherwise
applicable vesting or performance conditions of an Award. Such events may include, but shall not be limited to, failure to remit the amounts necessary to satisfy the Participant’s tax withholding obligations, termination of employment for
Cause, termination of the Participant’s provision of services to the Company, Affiliate, and/or Subsidiary, violation of material Company, Affiliate, and/or Subsidiary policies, breach of noncompetition, confidentiality, or other restrictive
covenants that may apply to the Participant, or other conduct by the Participant that is detrimental to the business or reputation of the Company, its Affiliates, and/or its Subsidiaries. 

(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of
misconduct, with any financial reporting requirement under the securities laws, if the Participant knowingly or grossly negligently engaged in the misconduct, or knowingly or grossly negligently failed to prevent the misconduct, or if the
Participant is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002, the Participant shall, to the extent required by Section 304 of the Sarbanes-Oxley Act of 2002, reimburse the
Company the amount of any payment in settlement of an Award earned or accrued during the twelve (12) month period following the first public issuance or filing with the United States Securities and Exchange Commission (whichever just occurred)
of the financial document embodying such financial reporting requirement. 
 (c) To the extent that any policy adopted by Baxalta in order
to comply with regulations issued pursuant to Section 10D of the Exchange Act, as required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, requires any Participant to forfeit any Award, or repay any amount
paid with respect to any Award, such policy shall be deemed incorporated into all outstanding Awards to the extent required by such regulations, and all Participants subject to such regulations, by accepting any Award, shall be deemed to have
consented to the inclusion of provisions in their Agreement as determined by the Committee to be necessary or appropriate to comply with such regulations. 

8.7 Withholding. All Awards and other payments under the Plan are subject to withholding of all applicable taxes, which
withholding obligations may be satisfied, with the consent of the Committee, through the surrender of Shares which the Participant already owns or to which a Participant is otherwise entitled under the Plan; provided, however, with the consent of
the Committee, previously-owned Shares that have been held by the Participant or Shares to which the Participant is entitled under the Plan may only be used to satisfy the minimum tax withholding required by applicable law (or other rates that will
not have a negative accounting impact). 
 8.8 Transferability. Awards under the Plan are not transferable except as
designated by the Participant by will or by the laws of descent and distribution or, to the extent provided by the Committee, pursuant to a qualified domestic relations order (within the meaning of the Code and applicable rules thereunder). To the
extent that the Participant who receives an Award under the Plan has the right to exercise such Award, the Award may be exercised during the lifetime of the Participant only by the Participant. Notwithstanding the foregoing provisions of this

  
 18 

 
subsection 8.5, the Committee may permit Awards under the Plan to be transferred to or for the benefit of the Participant’s family (including, without limitation, to a trust or partnership
for the benefit of a Participant’s family), subject to such procedures as the Committee may establish. In no event shall an Incentive Stock Option be transferable to the extent that such transferability would violate the requirements applicable
to such option under section 422 of the Code. 
 8.9 Notices. Any notice or document required to be filed with the
Committee under the Plan will be properly filed if delivered or mailed by registered mail, postage prepaid, to the Committee, in care of Baxalta at its principal executive offices. The Committee may, by advance written notice to affected persons,
revise such notice procedure from time to time. Any notice required under the Plan (other than a notice of election) may be waived by the person entitled to notice. 

8.10 Form and Time of Elections. Unless otherwise specified herein, each election required or permitted to be made by any
Participant or other person entitled to benefits under the Plan, and any permitted modification or revocation thereof, shall be in writing filed with the applicable Committee at such times, in such form, and subject to such restrictions and
limitations, not inconsistent with the terms of the Plan, as the Committee shall require. 
 8.11 Agreement With Baxalta or
Subsidiary. At the time of an Award to a Participant under the Plan, the Committee may require a Participant to enter into an agreement with Baxalta or the Subsidiary, as applicable (the “Agreement”), in a form specified by the
Committee, agreeing to the terms and conditions of the Plan and to such additional terms and conditions, not inconsistent with the Plan, as the Committee may, in its sole discretion, prescribe. 

8.12 Limitation of Implied Rights.  
  

	 	(a)	Neither a Participant nor any other person shall, by reason of the Plan, acquire any right in or title to any assets, funds or property of the Company whatsoever, including without limitation, any specific funds,
assets, or other property which the Company, in its sole discretion, may set aside in anticipation of a liability under the Plan. A Participant shall have only a contractual right to the amounts, if any, payable under the Plan, unsecured by any
assets of the Company. Nothing contained in the Plan shall constitute a guarantee by the Company any Subsidiary that the assets of such companies shall be sufficient to pay any benefits to any person. 

 

	 	(b)	The Plan does not constitute a contract of employment or continued service, and selection as a Participant will not give any employee the right to be retained in the employ or service of the Company, nor any right or
claim to any benefit under the Plan, unless such right or claim has specifically accrued under the terms of the Plan. Except as otherwise provided in the Plan, no Award under the Plan shall confer upon the holder thereof any right as a shareholder
of Baxalta prior to the date on which he fulfills all service requirements and other conditions for receipt of such rights and Shares are registered in his name. 

  
 19 

 8.13 Evidence. Evidence required of anyone under the Plan may be by
certificate, affidavit, document or other information which the person acting on it considers pertinent and reliable, and signed, made or presented by the proper party or parties. 

8.14 Action by Baxalta or Subsidiary. Any action required or permitted to be taken by Baxalta or any Subsidiary shall be
by resolution of its board of directors or by action of one or more members of the board (including a committee of the board) who are duly authorized to act for the board or (except to the extent prohibited by applicable law or the rules of any
stock exchange) by a duly authorized officer of Baxalta. 
 8.15 Gender and Number. Where the context admits, words in
any gender shall include any other gender, words in the singular shall include the plural and the plural shall include the singular and the term “or” also means “and/or” and the term “including” means “including
but not limited to”. 
 8.16 Applicable Law. The provisions of the Plan shall be construed in accordance with the
laws of the State of Delaware, without giving effect to choice of law principles. 
 8.17 Foreign Employees.
Notwithstanding any other provision of the Plan to the contrary, the Committee may grant Awards to eligible persons who are foreign nationals on such terms and conditions different from those specified in the Plan as may, in the judgment of the
Committee, be necessary or desirable to foster and promote achievement of the purposes of the Plan. In furtherance of such purposes, the Committee may make such modifications, amendments, procedures and subplans as may be necessary or advisable to
comply with provisions of laws in other countries or jurisdictions in which Baxalta or a Subsidiary operates or has employees. 

SECTION 9 

AMENDMENT AND TERMINATION  

The Board may, at any time, amend or terminate the Plan, and the Board or the Committee may amend any Agreement, provided that no amendment or
termination may, in the absence of written consent to the change by the affected Participant (or, if the Participant is not then living and if applicable, the affected Beneficiary), adversely affect the rights of any Participant or, if applicable,
Beneficiary under any Award granted under the Plan prior to the date such amendment is adopted by the Board (or the Committee, if applicable); and further provided that adjustments pursuant to subsection 5.2 shall not be subject to the foregoing
limitations of this Section 9; and further provided no amendment shall be made to the provisions of subsection 6.8 (relating to Option and SAR repricing) without the approval of Baxalta’s shareholders; and provided further, that no other
amendment shall be made to the Plan without the approval of Baxalta’s shareholders if the approval of Baxalta’s shareholders of such amendment is required by law or the rules of any stock exchange on which Shares are listed. It is the
intention of Baxalta that, to the extent that any provisions of this Plan or any Awards granted hereunder are subject to Section 409A of the Code, the Plan and the Awards comply with the requirements of Section 409A of the Code and that
the Plan and Awards be administered in good faith in accordance with such requirements and the Committee shall have the authority to amend any outstanding Awards to conform to the requirements of Section 409A. Without limiting the

  
 20 

 
generality of the foregoing, to the extent that any Award is determined in good faith by the Committee to constitute deferred compensation subject to Section 409A (a “Section 409A
Award”) then (i) if vesting or settlement of the Section 409A Award is conditioned upon termination of employment, and the Participant incurs a termination of employment that is not also a separation from service as defined in
Section 409A, then the Award shall vest as of the date of the termination of employment, but payment shall be deferred until the Participant incurs a separation from service or dies, and (ii) if a Participant is a specified employee as
defined in the Baxter International Inc. and Subsidiaries Deferred Compensation Plan on the date he incurs a separation from service, then payment of any amount with respect to an Section 409A Award that becomes payable by reason of such
separation from service (including amounts deferred pursuant to the preceding clause) shall be deferred until the earlier of the first day of the seventh month following the month that includes the separation from service or the Participant’s
death. Notwithstanding the foregoing, the Company does not guarantee that Awards under the Plan will comply with section 409A and the Committee is under no obligation to make any changes to any Awards to cause such compliance. 

  
 21EX-10.2(a)

 Exhibit 10.2(a) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 MASTER SERVICES AGREEMENT 

This Master Services Agreement (the “Agreement”) is made and entered into as of February 27, 2015 (the
“Effective Date”), by and between Worldwide Clinical Trials, Inc., with offices at 401 North Maple Drive, Beverly Hills, California 90210 (together with its Affiliates, “WCT”) and Coherus BioSciences, Inc., with
offices at 201 Redwood Shores Parkway Suite 200 Redwood City, CA 94065 (“Sponsor”), both hereinafter referred to as the “Parties”. 

For purposes of this Agreement, “Affiliates” means any entity that controls, is controlled by or is under common control
with, that Party. “Control” means the possession, directly or indirectly, of at least 50% of the share capital or voting rights or of the power to direct or cause the direction of the management and policies of an entity, whether
through the ownership of voting securities, by contract or otherwise. 
 WHEREAS, Sponsor is engaged in the research and development of
pharmaceutical products; 
 WHEREAS, WCT is engaged in providing services to pharmaceutical manufacturers in support of their clinical
research and product development activities; 
 WHEREAS, Sponsor wishes to retain WCT, from time to time, to assist in certain product
development activities relating to certain of Sponsor’s clinical studies (each of which shall be referred to as a “Study”); and 

WHEREAS, Sponsor agrees to compensate WCT for its services. 

NOW THEREFORE, in consideration of the premises and the mutual promises and undertakings herein contained, the receipt and sufficiency of
which is hereby acknowledged, the Parties agree as follows: 
  

	1.0	SERVICES 

 WCT, itself or through one of its Affiliates (if applicable) hereby agrees to perform the
services (the “Services”) in accordance with the terms of this Agreement and any associated Work Order(s) (as hereinafter defined). In the event that Sponsor requires the performance of Services, it shall enter into a Work Order,
defined as a separate written agreement between Sponsor and WCT, specifying the basic parameters of a project, including, without limitation, the assumptions, the costs, payment schedule, and the time period for completing a project, or, as
applicable, other Services to be performed by WCT for Sponsor (the “Work Order”). The Work Order shall be in form as attached hereto as Exhibit A and shall reference this Agreement and incorporate these terms. To the extent
any term or provision of a Work Order conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall prevail, except to the extent the Parties agree, or the applicable Work Order expressly and specifically
states an intent to supersede this Agreement on a specific matter. 
  

	1.1	Performance 

 WCT shall use its commercially reasonable efforts to perform the Services within the
estimated time frame set forth in Attachment D of the applicable Work Order. Such time estimate assumes[***], and to the extent that the Services are delayed due to [***], such time estimates shall be subject to adjustment and resulting costs, as to
be agreed to by the Parties in writing. 

  
 1 

	1.2	Compliance with Laws/Agreements 

 The Parties shall perform their obligations under this Agreement and
each Work Order in accordance with the terms of this Agreement, the applicable Work Order, applicable provisions of the Study protocol, agreed upon Standard Operating Procedures, the current Guidelines for Good Clinical Practice, the Declaration of
Helsinki of the 41st World Medical Assembly, South Africa 1996 as amended, and all other applicable laws and regulations. 
 The Parties and their
respective owners, officers, directors, employees or agents have not and shall not pay, give, offer or promise to pay or give, or authorize the payment, directly or indirectly, of any money or anything of value to any foreign government official or
employee (including employees of state-owned institutions), for the purpose of (i) influencing any act or decision of such official or of such government, (ii) inducing that person to do or omit doing any act in violation of his or her
lawful duty, (iii) securing an improper advantage, or (iv) influencing such official to use his influence with the government to effect or influence the decision of such government, in order to assist Sponsor or WCT in obtaining or
retaining business for or with or directing business to any person. 
 Each Party agrees to comply with all applicable anticorruption laws, rules and
regulations. The Parties agree to reasonably cooperate with each other’s diligence efforts in order to satisfy each Party’s obligations under the United States Foreign Corrupt Practices Act, as amended (“FCPA”), the UK Bribery
Act and any implementing legislation under the OECD Convention Against Bribery of Foreign Government Officials in International Business Transactions. Each Party represents, warrants and covenants that it maintains adequate internal controls and
accurate books and records to the extent required in order to comply with applicable anti-corruption laws. 
  

	1.3	Transfer of Obligations 

 Each Work Order shall constitute a unique agreement and shall stand alone with
respect to any other Work Order entered into under this Agreement. As required under Title 21 CFR Part 312.52, the Parties shall document in writing the transfer by Sponsor to WCT of any of Sponsor’s responsibilities under Title 21 CFR Part
312, Subpart D. Notwithstanding the foregoing, Sponsor will retain the ultimate authority and control over and responsibility for each Study. 
  

	1.4	Changes 

 The terms of a Work Order may be amended or modified by mutual written agreement of WCT and
Sponsor. Sponsor may request changes to a Work Order or, if WCT believes a change in the scope or scale of Services is necessary or advisable based on changes to mutual assumptions upon which a Work Order, and/or timelines were made, WCT shall so
advise Sponsor. In either case, the Parties will [***] and negotiate and execute [***] a proposed change order (“Change Order”) to the applicable Work Order [***] days. The Change Order shall be substantially in the form set forth
in Exhibit B. In the event WCT provides additional services or expends resources at Sponsor’s written request and in strict accordance with Sponsor’s requirements, in the absence of a Change Order, Sponsor will compensate and/or
reimburse WCT for all reasonable fees and reasonable costs incurred. 
  

	2.0	WORK PRODUCT 

 During the term of each Work Order, WCT shall maintain all materials and all other data or
documents included in the Trial Master File obtained or generated by WCT in the course of providing the relevant Services in accordance with WCT’s standard operating procedures, including all computerized records and files (“Work
Product”), in a secure area reasonably protected from fire, theft and destruction. At the expiration or termination of a Work Order and subject to satisfaction of the Parties’ obligations thereunder, Sponsor shall provide WCT with
written instructions as to the disposition of the Work Product created under that Work Order. Such written instructions will provide that WCT (a) deliver the Work Product, in the form in which WCT currently holds

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

2 

 
them, to a designated Sponsor location or to such other entity or at such other address as Sponsor may specify, (b) retain the materials for the period of time specified in the Work Order,
or (c) destroy all such materials except for those which WCT is required by law or regulation to store or maintain. Upon expiration or termination of a Work Order, any storage, destruction or shipping costs or services relating to such
disposition of the Work Product will be [***]. Notwithstanding the foregoing, WCT may retain copies of any portion of the Work Product as may be reasonably necessary for regulatory or insurance purposes and one electronic, archival backup copy in
accordance with WCT’s Data Retention Policy, subject to its ongoing obligation to maintain the confidentiality of such materials. 
  

	3.0	PAYMENT AND COMPENSATION 

 The Parties agree that the fees and other reimbursements that WCT will receive
for performing the Services hereunder will be outlined in each Work Order and are subject to the following terms and conditions. 
  

	3.1	Compensation for Services 

 As compensation for providing the Services, Sponsor shall pay WCT in
accordance with the terms in this Agreement and each applicable Work Order. Each Work Order will include as attachments a Study budget containing WCT’s estimated service fees and Pass-through Expenses (the “Budget”), a payment
schedule (the “Payment Schedule”) and a timeline showing performance milestones (the “Timeline”). 
  

	3.2	Pass-through Expenses 

 Sponsor will reimburse WCT for [***], exclusive of grant payments (described
below), incurred by WCT as identified in the Budget or otherwise approved by the Sponsor which WCT will invoice to the Sponsor without mark-up (“Pass-through Expenses”). Pass-through Expenses shall include, but shall not be limited
to [***]. 
  

	3.3	Invoices 

 WCT shall submit a reasonably detailed separate invoice by email to Sponsor ([***]) on a
monthly basis for Services, Pass Through Expenses and Investigator/Institution Fees with appropriate supporting summary documentation. [***]. WCT shall retain original receipts for review by Sponsor upon Sponsor’s written request. 

 

	3.4	Payment Terms 

 Sponsor agrees to pay for Services and Pass-through Expenses in accordance with the
Payment Schedule outlined in each Work Order or associated Change Order. Sponsor will pay for all Services, Pass-through Expenses and other invoiced items within [***] days of receipt of an invoice. All payments will be made in the currency noted in
the Work Order. All fees for Services and Pass-through Expenses under this Agreement are stated [***]. [***]. 
 Payments shall be made by Sponsor via wire
transfer or check (at Coherus’s option) with the address/wiring instructions set forth in the applicable Work Order. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

3 

	3.5	Project Delays 

 In the event Sponsor delays, suspends or places a hold on the Study for any reason,
Sponsor shall promptly provide WCT with written notice of such delay, hold or suspension, and Sponsor and WCT will, within [***] days of such notice, agree on appropriate revisions to the applicable Work Order and each Party will complete its
respective duties and obligations as described in any resulting Change Order. During the period following WCT’s receipt of Sponsor’s notice of delay, hold or suspension, Sponsor will [***]. 

In the event that a Study is delayed or placed on-hold for more than [***] days, Sponsor shall have the right to retain[***] all [***] for the duration of the
delay or on-hold period. If Sponsor does not wish to retain any [***] for the duration of the delay or on-hold period, WCT shall have the right to reallocate any and all [***] after such [***] day period. If the delay or on-hold period continues for
[***], either Party may, by provision of written notice, terminate the applicable Work Order. 
  

	3.6	Currency Management 

 For service fees, the bid currencies will be tracked and managed against the
contract currency established in each Work Order. At the end of each calendar quarter, a currency review may occur to assess the impact of currency fluctuation by comparing the actual average exchange rate(s) [***] to the currency exchange rate(s)
set out in the Work Order If the actual average exchange rate differs (up or down) by more than [***] from the currency exchange rate(s) in the applicable Work Order, WCT will apply this percent difference against the amounts invoiced for fees
[***]. Such currency exchange rate adjustment will be added (currency loss) or subtracted (currency gain) against the next invoice issued to Sponsor. If more than one bid currency is being tracked, the currency fluctuation review will compare [***]
set out in the applicable Work Order. 
  

	3.7	Disputed Invoices 

 In the event Sponsor disputes one or more items in an invoice, Sponsor will notify
WCT in writing within [***] days of receipt of the invoice and such notice shall contain [***]. WCT will respond to Sponsor within [***] days of receipt of the notification. This written communication pattern will continue [***]. Sponsor shall pay
the undisputed portion of the invoice in accordance with the payment terms and shall [***] pay the disputed amount within [***] days of resolution of the dispute. In the event the Parties are unable to reach a satisfactory resolution within [***]
days of the original invoice, either Party may [***]. 
  

	4.0	THIRD PARTY AGREEMENTS 

 WCT may contract with various third parties to perform part of the Services
provided that the party agrees in writing to be bound by terms regarding maintaining the confidentiality of proprietary information, and regarding ownership of intellectual property in connection with the Services; provided, however that any
subcontracting shall not relieve WCT of its obligations hereunder and WCT hereby agrees to manage the performance of any permitted assignee or subcontractor. For purposes of this Agreement, subcontractors do not include [***], provided that
WCT’s agreement with any such third party vendor includes a provision making Sponsor an intended third party beneficiary of the agreement with a right to enforce WCT’s rights under the agreement. Liability of WCT to Sponsor with

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

4 

 
respect to such third party vendors shall be [***]; however, WCT shall provide to Sponsor any amounts that WCT may recover from such vendors as a result of any error or service failure on the
part of such vendors in connection with Services under this Agreement. 
 If Sponsor requests that WCT use a particular third party and WCT does not wish to
contract with that third party based upon [***], then Sponsor shall contract directly with such provider (a “Sponsor Designated Vendor”) and, unless otherwise agreed in writing, WCT will have no responsibility for the selection,
instruction or supervision of such Sponsor Designated Vendor. 
  

	4.1	Institutions/Investigators 

 WCT’s Services under a Work Order may include identifying potential
medical institutions (“Institutions”) or clinical investigators (“Investigators”) (Institutions and Investigators together, the “Sites”) and/or negotiating, executing and/or administering contracts
with such parties which will govern their participation in the Study (“Clinical Trial Agreements”). If, pursuant to a Work Order, Sponsor delegates to WCT the responsibility for negotiating and/or executing Clinical Trial Agreements, the
following provisions will apply: 
  

	 	(a)	Sponsor may provide WCT with a list of suggested Sites to be recruited by WCT for a Study. WCT shall notify Sponsor in writing as to any listed Site with which WCT does not wish to contract. 

 

	 	(b)	Selection of all Sites will be subject to approval by Sponsor prior to initiation of any Study-related activities involving that Site or the start of any negotiations with such Site. 

 

	 	(c)	The Clinical Trial Agreement used with each Site will be in a form approved in advance by Sponsor. 

  

	 	(d)	In the event that local law prohibits Sponsor from being a party to a Clinical Trial Agreement, Sponsor (a) shall have the right to approve the Clinical Trial Agreement template; (b) shall be a named
third-party beneficiary to each Clinical Trial Agreement if possible; and (c) shall have the right but no obligation to approve all finalized Clinical Trial Agreements prior to execution by WCT. 

 

	 	(e)	If a Site requests indemnification from Sponsor, standard indemnification language, generated by the Sponsor, will be provided to the Site. If the Site requests changes to the standard language, WCT will negotiate with
the Site on Sponsor’s behalf and, if agreed, Sponsor will issue a letter of indemnification directly to the Site. Sponsor acknowledges that [***]. In addition, [***]. 

 

	 	(f)	The Sponsor may elect that grant payments to Sites be administered on its behalf by WCT, acting solely as payment agent unless otherwise agreed to by WCT in writing. WCT shall distribute all payments to Sites according
to the provisions of the applicable Clinical Trial Agreement and Work Order. Sponsor acknowledges and agrees that WCT will manage all administration of payments or other obligations to Sites for Services rendered in connection with relevant Studies
solely out of funds provided to WCT from Sponsor for this specific purpose. Furthermore, Sponsor acknowledges and agrees that WCT intends to maintain a cash neutral policy with regard to Site payments. In the event WCT or the Sites incur bank fees
with respect to the remittance of these grant payments, such fees will be borne by [***]. All payments to Sites and any associated bank fees will be made by WCT solely from the funds that have been specifically provided by Sponsor to WCT for this
purpose and not from WCT funds. [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

5 

 The Parties acknowledge and agree that, for the purposes of this Agreement or any Work Order, Sites shall not be
considered as employees, agents or subcontractors of WCT and that Sites will be required to exercise their own independent medical judgement. WCT’s responsibilities with respect to Sites shall be limited to those specifically set forth in the
applicable Work Order. 
  

	5.0	CONFIDENTIAL INFORMATION 

 The Parties acknowledge and agree that in the course of performing Services
hereunder, either Party may be exposed to or be given confidential or proprietary information of the other Party. Confidential Information shall mean all confidential information disclosed by or on behalf of a Party pursuant to this Agreement and/or
that certain Mutual Nondisclosure Agreement entered into by the Parties on July 16, 2014 (“Confidential Information”). The Parties agree to hold all Confidential Information in secrecy during the term of this Agreement and for
a period of [***] years from the date of disclosure hereof and shall disclose Confidential Information to third parties only on a need-to-know basis. Without limiting the generality of the foregoing, Confidential Information shall include, without
limitation, all commercial, technical, scientific, or medical information, trade secrets, know-how, financial information, protocols, brochures, formulations, research and development programs and strategies, methodology, testing techniques,
analytical test method, test samples and prototypes, information gathered or viewed during a site visit, audit or inspection of a Party, analyses, software, source codes and technological or other know-how. All information or data collected or
otherwise generated by a Party directly in providing the Services pursuant to this Agreement and or a Work Order shall be Sponsor’s Confidential Information. Confidential Information shall be deemed to be all such information given by the
disclosing Party to the receiving Party except for information which is (i) publicly available or later becomes publicly available through no fault of the receiving Party; (ii) obtained by the receiving Party from a third Party entitled to
disclose it; (iii) already in possession of the receiving Party as indicated in its written records; (iv) independently developed by the receiving Party without use of the Confidential Information; or (v) required by any law, rule,
regulation, order, decision, decree, or subpoena or other judicial, administrative, or legal process to be disclosed. 
 The receiving Party shall use the
disclosing Party’s Confidential Information only for purposes set forth in the Agreement and the applicable Work Order and shall disclose Confidential Information only to its employees, Affiliates, agents, third party vendors, investigators,
consultants and subcontractors who have a need to know. The terms and conditions of this Agreement and any Work Order shall be deemed Confidential Information. 

Both Parties shall ensure that all of its officers, employees, consultants, agents, investigators or contractors who receive such Confidential Information
understand and shall be bound by a binding written agreement to confidentiality and non-use provisions at least as stringent as the confidentiality and non-use obligations in this Agreement. 

Unless otherwise agreed in writing, within [***] days after the termination of the Agreement or the written request by the disclosing Party, and if the
disclosing Party is Sponsor, Sponsor’s payment of all outstanding invoices, the receiving Party shall return to the disclosing Party all Confidential Information in documentary or permanent form including any and all copies thereof, except for
one archival copy that the receiving Party can keep for its records (which may be electronic). 
 The Parties agree that each Party is and shall remain the
exclusive owner of its Confidential Information and all patent, copyright, trade secret and other intellectual property rights therein unless and until a further agreement is executed. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

6 

 The Parties acknowledge that any violation of the terms of this Section 5 may result in irreparable injury
and damage to disclosing Party that is not adequately compensable in money damages, and for which disclosing Party may have no adequate remedy at law. Accordingly, the receiving Party agrees that the disclosing Party shall be entitled to seek
(without waiving any additional rights or remedies, including monetary damages, otherwise available to the disclosing Party at law, in equity, or by statute) preliminary and permanent injunctive relief in the event of a breach or intended or
threatened breach by the receiving Party. 
  

	6.0	OWNERSHIP OF DATA AND INTELLECTUAL PROPERTY 

 Any invention, discovery, or improvement directly related
to Sponsor’s products or technology which is conceived or reduced to practice as a direct consequence of WCT’s performance of the Services hereunder, which inextricably incorporate Work Product (defined below) and/or Sponsor Confidential
Information (the “Inventions”) is Sponsor’s property and shall be used by Sponsor as Sponsor deems appropriate. WCT hereby assigns to Sponsor any and all right, title and interest in Sponsor’s Inventions. WCT agrees to
execute and have executed assignments of the Inventions to Sponsor, along with other documents that are necessary or helpful to Sponsor in filing patent applications, or which may relate to any litigation or interference and/or controversy in
connection therewith. The entire control, prosecution, and conduct of any patent application filed by Sponsor shall be outside the jurisdiction of and without expense to WCT and its officers, employees, representatives and agents. WCT acknowledges
that Sponsor has the exclusive right to file patent applications in connection with the Inventions. WCT warrants that neither it, nor its employees, agents and representatives, will prevent Sponsor from filing patent applications for, or from
applying the results of the research carried out for Sponsor hereunder. 
 All reports, data, technical information, original works of authorship and all
other information, furnished by or on behalf of Sponsor, or created specifically for Sponsor as a deliverable under a Work Order (“Work Product”), shall be the sole property of Sponsor. Nothing under this Section or any other
Section of this Agreement shall be construed as (i) granting to any Party any rights under any patent, copyright or other intellectual property right of the other Party (ii) granting to any Party any rights in or to the Confidential
Information of the other Party other than the limited right to use such Confidential Information solely for the purposes expressly permitted by Section 5 of this Agreement. 

Sponsor acknowledges that all computer programs, applications, algorithms, databases, methods, techniques, processes and other materials and ideas used
by WCT in performance of the work under this Agreement, and not supplied to WCT by Sponsor (“WCT Works”), are the exclusive property of WCT or its licensors. Sponsor agrees that any improvements, alterations or enhancements to the
WCT Works during the term of this Agreement or the Study shall be the sole property of WCT. Subject to Section 5 hereof, in no event shall WCT be precluded from use of its general knowledge, skills and experience, and any of its ideas,
concepts, know-how and techniques used or developed by it in the course of providing Services under this Agreement. 
  

	7.0	TERM AND TERMINATION 

  

	7.1	Term 

 This Agreement shall commence on the Effective Date and, unless otherwise terminated, shall
continue until the later of three (3) years from the Effective Date or the final payment is received for all Work Orders entered into pursuant hereto. Termination of a Work Order shall not affect any other Work Order; each Work Order shall
continue in full force and effect until its expiration date or final payment is received, unless specifically earlier terminated in accordance with the terms of this Agreement or the terms of that Work Order. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

7 

	7.2	Termination for Material Breach 

 In the event that either Party commits a material breach in any of the
terms or conditions of this Agreement or a Work Order, and that Party fails to cure the breach within thirty (30) days after receipt of notice of the default or breach from the other Party, the Party giving notice may, at its option,
immediately terminate this Agreement, or the Work Order, as applicable, at the end of the 30-day period. For the avoidance of doubt, [***]. 
  

	7.3	Termination by Sponsor without Cause 

 Sponsor shall have the right to terminate this Agreement or a Work
Order (for other than breach by WCT) at any time by giving appropriate written notice at least ninety (90) days prior to the desired termination date. 
  

	7.4	Termination by WCT without Cause 

 WCT shall have the right to terminate this Agreement (for other than
breach by Sponsor) at any time by giving appropriate written notice at least ninety (90) days prior to the desired termination date provided, however, if WCT terminates this Agreement while any Work Order remains in effect, the terms of this
Agreement will continue in force until WCT has completed the Services under the applicable Work Order and has received full payment therefor. 
  

	7.5	Termination for Other Reasons 

 Sponsor shall have the right to terminate a Work Order effective
immediately due to patient safety by giving written notice to WCT. Either Party shall have the right to terminate this Agreement and/or one or more Work Orders at any time upon receipt of written notice to the other Party, if the other Party shall
be adjudicated insolvent or shall petition for or consent to any relief under any insolvency, re-organization, receivership, liquidation, compromise, or any moratorium statute, whether now or hereafter in effect, or shall make an assignment for the
benefit of its creditors, or shall petition for the appointment of a receiver, liquidator, trustee, or custodian for all or a substantial part of its assets, or if a receiver, liquidator, trustee or custodian is appointed for all or a substantial
part of its assets and is not discharged within thirty (30) days after the date of such appointment. In the event that any of the above events occur, that Party shall immediately notify the other, in writing, of its occurrence. 

 

	7.6	Termination Procedures 

 Upon termination of this Agreement or any Work Order, the Parties will
reasonably cooperate with each other to provide for an orderly cessation of WCT’s Services. WCT shall [***] minimize costs associated with the cessation of the Services. In the event a Work Order is terminated, WCT shall [***]. In addition,
Sponsor shall [***]. If a Study, Work Order, or the Agreement is cancelled or terminated before the Services have been performed completely, [***]. . 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

8 

	8.0	DEBARMENT CERTIFICATION 

 WCT certifies that it has not been debarred under Section 306 of the
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §335a(a) or (b) or any equivalent local law or regulation. In the event that WCT becomes debarred, WCT agrees to notify Sponsor immediately. 

WCT certifies that it has not and will not use in any capacity the services of any individual, corporation, partnership, or association which has been
debarred under Section 306 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C §335a (a) or (b) or any equivalent local law or regulation. In the event that WCT becomes aware of or receives notice of the debarment of any
individual, corporation, partnership, or association providing services to WCT, which relate to the Services being provided under this Agreement, WCT agrees to notify Sponsor immediately. 

 

	9.0	RECORDS, AUDITS AND INSPECTIONS 

  

	9.1	Records 

 WCT shall maintain complete and accurate financial records relating to its performance of the
Services and Pass-through Expenses incurred in connection therewith for a period of [***] years or such later period as required by law. 
  

	9.2	Audits by Sponsor 

 During the term of each Work Order, WCT will permit representatives of Sponsor [***]
to examine, at a reasonable time during normal business hours, subject to at least [***] days prior written notice to WCT, and at Sponsor’s sole cost and expense: (i) the facilities where the Services are being, will be or have been
conducted; (ii) related Study documentation; and (iii) any other relevant information necessary for Sponsor to confirm that the Services are being or will be or have been conducted in conformance with applicable standard operating
procedures, the specific Work Orders, this Agreement, and in compliance with applicable laws and regulations. WCT will provide copies of any materials reasonably requested by Sponsor during such inspection. 

 

	9.3	Inspection by Regulatory Authorities 

 During the term of each Work Order, each Party will permit
regulatory authorities to examine: (i) the facilities where the Services are being conducted; (ii) Study documentation; and (iii) any other relevant information, including information that may be designated by one or both of the
Parties as confidential, reasonably necessary for regulatory authorities to confirm that the Services are being conducted in compliance with applicable laws and regulations. Each Party will immediately notify the other if any regulatory authority
schedules, or without scheduling, begins an inspection that relates to the Services or the Parties’ respective obligations hereunder. WCT (i) shall forward to Sponsor within [***] day any correspondence to such inquiry or inspection,
(ii) promptly notify Sponsor of any results of any such inquiry or inspection, including requested actions and (iii) Sponsor shall have the opportunity to have a representative present during any inspections where such regulatory or
government authority does not object and to comment on proposed responses given to the FDA or other regulatory or government authority prior to communication to the regulatory authority. 

 

	10.0	INDEMNIFICATION 

  

	10.1	Indemnification by WCT 

 WCT shall indemnify Sponsor and its officers, directors, employees and agents
from any loss, damage, cost or expense (including reasonable attorney’s fees) arising from any third party claim, demand, assessment, action, suit or proceeding (a “Claim”) caused by WCT’s (i) negligence or
intentional misconduct, (ii) material violation of any law or regulation in the performance of the Services and/or (iii) a material breach of this Agreement or a Work Order, all except to the extent such Claim is caused by Sponsor’s
negligence or wilful misconduct. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

9 

	10.2	Indemnification by Sponsor 

 Sponsor shall indemnify WCT and its Affiliates and their respective
officers, directors, employees and agents (the “WCT Group”) arising out of any Claim arising from (i) WCT’s performance of the Services or its obligations under this Agreement, the applicable Work Order, or any protocol
related thereto, (ii) the Study drug’s harmful or otherwise adverse effect, including, without limitation, a Claim based upon the consumption, sale, distribution or marketing of any substance, including the Study drug, (iii) [***]
other than WCT’s or its agents’ materials, Study drugs, study data, and study records (“Materials”); (iv) Sponsor’s subsequent use, failure to use, disclose or failure to disclose the results of the Services; or
(v) the material breach of this Agreement or the applicable Work Order, or the negligence or intentional misconduct or inaction of Sponsor, except to the extent such Claim is caused by WCT’s (i) negligence or wilful misconduct
(ii) material breach of this Agreement or Work Order and/or (iii) material violation of any law or regulation in the performance of the Services. 

In the event WCT incurs costs or expenses as a result of its becoming involved in, or being required to appear or otherwise participate in, a third party
matter [***]. The Parties agree to [***]. 
  

	10.3	Indemnification Procedures 

 Upon receipt of written notice of any Claim which may give rise to a right
of indemnity from the other Party hereto, the Party seeking indemnification (the “Indemnified Party”) shall give written notice thereof to the other Party (the “Indemnifying Party”). The Indemnified Party shall
permit the Indemnifying Party, at its own option and expense, to assume the complete defense of such Claim, provided that the Indemnified Party will have the right to participate in the defense of any such Claim at its own cost and expense. As to
those Claims with respect to which the Indemnifying Party does not elect to assume control, the Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense, at the Indemnifying Party’s own cost and
expense. The Indemnifying Party shall make no admission to, nor any settlement or agreement with any third party without the Indemnified Party’s prior written consent which consent shall not be unreasonably withheld, provided, however,
reasonable concession shall be made to comply with any requirements of the Indemnifying Party’s insurance policy. 
  

	11.0	LIMITATION OF LIABILITY 

 Except for the indemnification obligations of either Party under
Section 10, under no circumstances shall either Party be liable under this Agreement for any indirect, incidental, special or consequential damages of the other Party resulting from such Party’s performance or failure to perform under this
Agreement. In addition and except for the indemnification obligations of WCT under Section 10.1 and WCT’s breach of Section 5, in no event shall the collective, aggregate liability of the WCT Group to Sponsor exceed the [***] by WCT
from Sponsor pursuant to the Work Order from which such liability arose. 
  

	12.0	INSURANCE 

 For each applicable Work Order, Sponsor hereby represents and warrants that it shall maintain
adequate clinical trial and product liability insurance coverage, with insurance companies having an A. M. Best Rating of [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

10 

 [***] or better, consistent with industry standards to cover all personal injury, death or loss suffered as a
result of the Study drug, participation in the trial or the trial screening process. Other than as set forth in Section 10.1, to the extent that WCT provides depot services to Sponsor, [***]. Sponsor hereby acknowledges that [***]. Sponsor
shall provide WCT with a copy of Sponsor’s effective Certificate of Insurance or such other documented evidence to confirm that it has such coverage. Sponsor shall maintain such insurance for the entire duration of the Study and shall notify
WCT of any changes in coverage which impact the coverage requirements set forth above. 
 Prior to commencement of any work under this Agreement, WCT shall,
at its sole expense, maintain the following insurance on its own behalf, with insurance companies having an A. M. Best Rating of [***], or better: 

(1) [***]. The policy must be on an occurrence form and include the following limits: [***]. 

(2) [***]. This policy must include the following limits: [***]. 

(3) [***]: [***]. Throughout the term of this Agreement, the [***]. Upon expiration or termination of this Agreement, WCT will
either continue to maintain an active insurance policy, or purchase an extended reporting period coverage for claims first made and reported to the insurance company within [***] after the end of the Agreement. 

 

	13.0	REPRESENTATIONS AND WARRANTIES 

 Each Party represents that it is authorized to enter into this
Agreement, and any Work Order issued hereunder, and that the terms of this Agreement are not inconsistent with or a violation of any contracted or other legal obligation to which it is subject. 

Each Party represents that it has all qualifications, authorizations, licenses or permits which are necessary for performance of its obligations under this
Agreement. 
  

	14.0	DISCLAIMER 

 Sponsor acknowledges that the results of the Studies for which the Services are to be
provided hereunder are inherently uncertain and that, accordingly, there can be no assurance, representation or warranty by WCT that the product covered by this Agreement can, either during the term of this Agreement or thereafter, be successfully
developed or receive the required approval by the regulatory authorities. 
 Sponsor acknowledges that the development of the protocol concept and
scientific rationale shall be the sole responsibility of Sponsor regardless of WCT’s involvement in Study design or protocol-writing (or lack thereof). 
  

	15.0	EMPLOYEES; NON-SOLICITATION 

 WCT’s staff is not, nor shall they be deemed to be at any time during
the term of this Agreement, the employees of Sponsor. In consideration of the fees and benefits provided in this Agreement, each Party agrees that, without 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

11 

 the other Party’s prior written consent, during the term of this Agreement and for a period of [***]
following its expiration or other termination, neither Party shall directly or indirectly solicit for employment or contract, attempt to employ or contract with, or assist any other entity in employing, contracting with or soliciting for employment
or contract any employee who is at that time employed/contracted by a Party and who had been employed/contracted by such Party in connection with one or more Work Orders issued hereunder. This provision shall not be construed to prohibit the
advertisement of employment opportunities or job openings so long as such advertisements are not customized for, directed at or targeted at specific employees of the other Party nor prohibit the use of employment search firms so long as such firms
are not directed by the searching party to specifically target the other party’s employees, independent contractors, and consultants. In the event of a breach of this Section 15, [***]. The Parties expressly agree that [***]. In the event
that legal action becomes necessary for the enforcement of all or any part of this provision or to [***] provided for herein, the prevailing party shall receive in addition to any other damages or relief awarded, its reasonable attorneys’ fees,
together with appropriate costs and interest. The Parties acknowledge that in the event of a breach of this Section 15, the other Party shall be entitled to recover injunctive relief as well as [***], and that the [***] provision included
herein does not provide the Party with an adequate remedy at law for any such breach. 
  

	16.0	NOTICES 

 All notices provided for in this Agreement shall be in English and shall be sent by registered
first class mail, postage prepaid, return receipt requested, addressed to the respective Parties as follows: 
 If to Sponsor: 

Coherus BioSciences, Inc. 
 201
Redwood Shores Parkway Suite 200 
 Redwood City, CA 94065 

ATTN: General Counsel with a cc to the Chief Medical Officer 

If to WCT: 
 c/o Worldwide
Clinical Trials, Inc. 
 401 North Maple Drive 

Beverly Hills, California 90210 

ATTN: General Counsel 
  

	17.0	MISCELLANEOUS 

  

	17.1	Modification 

 This Agreement may be supplemented, amended or modified only by mutual agreement of the
Parties. No supplement, modification or amendment of this Agreement will be binding unless it is in writing and signed by both Parties. 
  

	17.2	Assignment 

 Neither Party shall have the right to assign this Agreement or any of the rights or
obligations hereunder without the prior written consent of the other Party, except that (a) [***] and (b) either Party may assign this Agreement to (i) an Affiliate or (ii) a purchaser of or successor to that area of its business
to which this Agreement is related (or, the case of Sponsor, the outstanding Work Orders relate), upon prior written notice, [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

12 

	17.3	Force Majeure 

 Neither Sponsor nor WCT shall be liable for delays in performing or any failure to
perform any of the terms of this Agreement or a Work Order caused by the effects of natural disaster, strike, war (declared or undeclared), insurrection, acts of terror, government sanction, restriction or prohibition, or other causes reasonably
beyond its control and without its fault, but the Party failing to perform shall use all commercially reasonable efforts to resume performance of this Agreement as soon as reasonably feasible. Any episode of force majeure which continues for [***]
days from the date of notification of its existence shall give the non-affected Party the right to terminate this Agreement upon [***] days additional notice. 
  

	17.4	Severability 

 If any provision of this Agreement is found by a court to be void, invalid or
unenforceable, the same shall either be reformed to comply with applicable laws and regulations or stricken if not so conformable, so as not to affect the validity or enforceability of the remaining provisions of this Agreement, except if the
principal intent of this Agreement is frustrated by such reformation or deletion in which case this Agreement shall terminate. 
  

	17.6	Entire Agreement 

 The Parties hereto acknowledge that each has read this Agreement, understands it and
agrees to be bound by its terms. The Parties agree that this Agreement, along with each Work Order, is the complete agreement between the Parties on the subject matter and supersedes all proposals (oral or written), letters of intent,
understandings, representations, conditions, warranties, covenants and other communications between the Parties relating to the same subject matter. 
  

	17.7	Survival 

 The terms contained in Sections 3, 10, 11and 17of this Agreement shall survive the completion
of performance, expiration or termination of this Agreement. Sections 5 and 6shall survive for the period expressly set forth in such Section or, if none, the applicable statute of limitations period applicable to a claim for breach of such
provision. 
  

	17.8	Governing Law 

 This Agreement shall be interpreted and enforced in accordance with the laws of the State
of California and each Party hereby specifically consents to the personal jurisdiction thereof. 
  

	17.9	Waiver 

 No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise
in any one or more instances will be deemed to be construed as a further or continuing waiver of such term, provision or condition or of any other term, provision or condition of this Agreement. 

 

	17.10	Independent Contractors 

 The Parties’ relationship, as established by this Agreement, is solely
that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Subject to Section 10.0 and/or as may be expressly agreed otherwise in a Work Order in the case
of legal representation in the EU, neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any
purpose whatsoever. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

13 

	17.11	Counterparts 

 This Agreement may be executed in counterparts, each of which shall be deemed an original
but all of which taken together shall constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission, by e-mail delivery of a “.pdf” format data file or other electronic means, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. 

 

	17.12	Arbitration 

 In the event a dispute relating to this Agreement or any Work Order arises between the
Parties, the Parties shall confer in good faith to resolve the dispute through negotiations between respective senior executives of the Parties. In the event that the Parties are unable to resolve the dispute, disputes shall be settled by
arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules in Los Angeles, California. Judgment shall be rendered by a mutually agreed upon single arbitrator. The provisions of this section may be
enforced by any court of competent jurisdiction, and the Party seeking enforcement shall be entitled to an award of all costs, fees and expenses, including reasonable attorneys’ fees, to be paid by the party against whom enforcement is ordered.

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed by their respective duly authorized representatives
effective as of the Effective Date. 
  

									
	COHERUS BIOSCIENCES, INC.				WORLDWIDE CLINICAL TRIALS, INC.
					
	By:		 /s/ Dennis M. Lanfear
				By:		 /s/ Emily Hales

					
	Name:		Dennis M. Lanfear				Name:		Emily Hales
					
	Title:		Chief Executive Officer				Title:		Authorized Signatory
					
	Date:		3/9/2015				Date:		2 March 2015

 LIST OF EXHIBITS: 
  

							
	EXHIBIT A-1:				Form of Work Order Late Phase		
	EXHIBIT B:				Form of Change Order		

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

14 

 EXHIBIT A-1 

FORM OF WORK ORDER 
 LATE
PHASE 
 WORK ORDER # 

PROTOCOL NUMBER: 
 This
Work Order #    is made and entered as of the             day of
                    , 201     (the “Effective Date”) by and between
                    (“Sponsor”) and Worldwide Clinical Trials [Entity] (“WCT”). 

WHEREAS, Sponsor and WCT have entered into that certain Master Services Agreement dated
                    , 201     (hereinafter referred to as the “Agreement”); and 

WHEREAS, pursuant to the Agreement, WCT has agreed to perform certain Services in accordance with Work Orders from time to time entered
into by the Parties, as more fully provided in Section 1.0 of the Master Agreement, and Sponsor and WCT now desire to enter into such a Work Order, (the “Work Order”). 

WHEREAS, WCT and Sponsor desire that WCT provide certain Services with respect to
                                         
                                         
  , (the “Study”) for the study of the drug
                                        
(“Study Drug”). 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby
agree as follows: 
 1. Scope of Services. WCT shall perform the Services described in the Scope of Services, attached to this Work
Order as Attachment A (“Scope of Services”). 
 2. Compensation. For performance of these Services, Sponsor shall
pay to WCT the amounts set forth in the Budget set forth in Attachment B to this Work Order, which amounts shall be payable pursuant to the Payment Schedule set forth in Attachment C to this Work Order. 

3. Term and Termination. The term of this Work Order shall commence upon the effective date stated above and shall continue until
completion of Services as described in Attachment A, provided, however, the provisions of the Agreement shall govern its termination prior to completion. 

4. Incorporation by Reference; Conflict. The provisions of the Agreement are hereby expressly incorporated by reference into and made a
part of this Work Order. In the event of a conflict between the terms and conditions of this Work Order and those of the Agreement, the terms of the Agreement shall take precedence and control over those of this Work Order unless the Work Order
expressly and specifically states an intent to supersede the Agreement on a specific matter by reference. Unless otherwise specifically defined herein, each term used herein which is defined in the Agreement shall have the meaning assigned to such
term in the Agreement. 
 5. Timely Completion. The timeline for this Work Order is attached as Attachment D. 

6. Currency. All invoices and amounts to be paid shall be in USD. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Work Order effective as of the Effective Date. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

15 

											
	Worldwide Clinical Trials [Entity]		Coherus BioSciences, Inc.		
						
	By:		 Sample
				By:		 Sample
		
						
	Name:						Name:				
						
	Title:						Title:				
						
	Date:						Date:				

 LIST OF ATTACHMENTS: 
  

					
	ATTACHMENT A:				SCOPE OF SERVICES
	ATTACHMENT B:				BUDGET
	ATTACHMENT C:				PAYMENT SCHEDULE
	ATTACHMENT D:				TIMELINE

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

16 

 WORK ORDER ATTACHMENT C 

PAYMENT SCHEDULE 
  

	1.	Service Fees (To be billed separately) 

  

	 	1.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, [***] of this Work Order, Sponsor will [***] which represents [***]. All subsequent invoices will be submitted to Sponsor by email based on the
Payment Schedule. With the exception of [***], which shall be due within xx (xx) days of Sponsor’s receipt of an invoice for same, payment terms shall be as defined in the Agreement. Any outstanding balances will be reconciled [***].
Service Fees shall be invoiced separately from Pass-through Expenses and Investigator/Institution Fees. 

  

	 	1.2.	Payment shall be issued by check or wire transfer at Sponsor’s option. Wiring instructions are as follows: 

Account Holder: 
 Bank Name:
Bank Address: 
 ABA No.: 

Bank Account No.: 
 Routing:

 Swift Code: 
  

	2.	Pass-through Expenses (To be billed separately) 

  

	 	2.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, [***] of this Work Order, Sponsor will [***] which represents [***]. WCT will submit subsequent monthly invoices by email for incurred Pass-through
Expenses based on actuals. With each subsequent invoice for Pass-through Expenses, WCT will [***]. With the exception of [***], which shall be due within xx (xx) days of Sponsor’s receipt of an invoice for same, payment terms shall be as
defined in the Agreement. Any outstanding balances will be reconciled [***]. 

  

	3.	Investigator/Institution Fees (To be billed separately) 

  

	 	3.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, [***] of this Work Order, Sponsor will [***] which represents [***]. Periodically, WCT will invoice Sponsor by email to [***]. The invoice will be
accompanied by a report which [***]. If an increase in the amount of anticipated Investigator/Institution grants is necessary, WCT will provide appropriate support justifying such increase. With the exception of [***], which shall be due within xx
(xx) days of Sponsor’s receipt of an invoice for same, payment terms shall be as defined in the Agreement. Any outstanding balances will be reconciled and provided [***]. For avoidance of doubt, WCT will make all grant payments only from
funds received from Sponsor specifically for this purpose. WCT shall not [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

17 

	4.	Accounting close out for items 1, 2 and 3 above 

  

	 	4.1.	After [***] days following the end of the study, the presumption shall be that no further payments are owed by Sponsor to WCT for Service Fees. After [***] days following the end of the study, the presumption shall be
that no further payments will be made by Sponsor to WCT for Pass-through Expenses. Accordingly, Sponsor shall have a right to a refund of any amounts of the prepayments made in according to sections 1 through 3 above which exceed the aggregate
actual expense. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

18 

 EXHIBIT B 

FORM OF CHANGE ORDER 
  

					
	Sponsor:	  	WCT Project Manager:	  	
	Protocol Number:	  	WCT ID:	  	
	Change Order #:	  	Date:	  	

 Worldwide Clinical Trials [Entity] (“WCT”) and Sponsor Name (“Sponsor”) entered into a Work Order dated [effective date] (“Work Order”) [as amended by Change Order # 1 effective [effective date]] [and further amended by Change Order # 2 effective [effective date]] in which WCT was to
provide certain Services to Sponsor in connection with Study [insert Protocol number] (“Study”). WCT and Sponsor wish to
amend the Work Order as follows: 
 1. Revisions to the Scope of Services including timelines). The Scope of Services has been revised as described
below, and WCT will provide the following additional services [will not provide the following services initially contracted]: 

 

					
	 Description of Service
	  	 Target Completion Date
	  	 Costs

		  		  	
		  		  	
		  		  	

 2. Revisions to the Study Budget. As a result of the changes to the Services and Scope of Services, this Change Order #[Insert] [increases] [decreases] the Service fees as shown above. A revised total
budget value is below. 
  

							
	 	  	Services Fees	  	Estimated Pass
Through Costs	  	Total
	 Original Work Order Value:
	  		  		  	
	 Change Order #1 Value:
	  		  		  	
	 [Add additional Change Orders as necessary]
	  		  		  	
	 Revised Contract Value:
	  		  		  	

 3. Revisions to the Payment Schedule. A revised and restated payment schedule, as amended by Change Order #[Insert#] is detailed below. 

Payment Schedule, as amended by Change Order #[Insert] 
 Except to the extent specifically modified by this Change Order #[Insert], the provisions of the Work Order remain unmodified and the Work Order as amended by this Change Order #[Insert] is confirmed as being in full force and effect. All defined terms within the Work Order shall have the same meaning when used herein.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

19 

 Authorized representatives of the Parties have executed this Change Order # [insert] effective as of the Effective Date written above. 
  

											
	Worldwide Clinical Trials [Entity]		Coherus BioSciences, Inc.		
						
	By:		 Sample
				By:		 Sample
		
						
	Name:						Name:				
						
	Title:						Title:				
						
	Date:						Date:				

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]